Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Debt to Equity (2016 - 2023)

Arcadia Biosciences filings provide 10 years of Debt to Equity readings, the most recent being $0.0 for Q1 2023.

  • On a quarterly basis, Debt to Equity fell 60.61% to $0.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $0.0, a 60.61% decrease, with the full-year FY2022 number at $0.0, up 11.95% from a year prior.
  • Debt to Equity hit $0.0 in Q1 2023 for Arcadia Biosciences, down from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.24 in Q2 2020 to a low of $0.0 in Q1 2023.
  • Median Debt to Equity over the past 5 years was $0.01 (2019), compared with a mean of $0.04.
  • Biggest five-year swings in Debt to Equity: soared 16968.63% in 2020 and later crashed 98.51% in 2021.
  • Arcadia Biosciences' Debt to Equity stood at $0.02 in 2019, then skyrocketed by 333.39% to $0.08 in 2020, then plummeted by 97.32% to $0.0 in 2021, then rose by 11.95% to $0.0 in 2022, then tumbled by 60.87% to $0.0 in 2023.
  • The last three reported values for Debt to Equity were $0.0 (Q1 2023), $0.0 (Q4 2022), and $0.0 (Q3 2022) per Business Quant data.